Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review

Gynecologic Oncology
Dana M RoqueAlessandro D Santin

Abstract

To describe the clinical outcome and tolerability of weekly ixabepilone (16-20mg/m(2) days 1, 8, 15 of a 28-day cycle)±biweekly bevacizumab (10mg/kg days 1 and 15) in patients with recurrent/persistent uterine or ovarian/primary peritoneal/fallopian tube cancers. A single-institution retrospective review was performed inclusive of all patients who received ≥2cycles from 01/2010 to 06/2014. Progression-free (PFS) and overall (OS) survival were determined using the Kaplan-Meier method. Toxicities were graded according to CTCAEv4.0. Best response was categorized using RECIST or by CA-125 criteria. A total of 60 patients (24 uterine and 36 ovarian cancers) were identified. Patients had received a median of 3.5 (range:1-10) prior lines of chemotherapy. Patients completed a mean of 4.7±2.9cycles of ixabepilone; 66.7% (16/24) and 91.7% (33/36) of patients with uterine and ovarian cancers received concurrent bevacizumab. For uterine cancers, objective response rate (ORR) was 41.7% (12.5% complete, 29.2% partial); median duration of response or stabilization was 7months (range:2-30). Median PFS and OS were 5.2 and 9.6months, respectively. PFS and OS were improved in the setting of concurrent bevacizumab (6.5 versus 3.0months, p=0.01, HR...Continue Reading

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gordon J S Rustin
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerJoel I Sorosky
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 18, 2008·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Franco OdicinoWilliam T Creasman
Mar 19, 2008·Cancer Chemotherapy and Pharmacology·Francis Y F LeeGregory Vite
Apr 16, 2009·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Sergio Pecorelli
Feb 22, 2011·Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine·UNKNOWN U.S. Department of Health and Human Services
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol AghajanianKimberly K Leslie
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Dec 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B J MonkR A Burger
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard

❮ Previous
Next ❯

Citations

Dec 3, 2015·Expert Opinion on Pharmacotherapy·Christopher de HayduAlessandro D Santin
Mar 8, 2016·Expert Opinion on Investigational Drugs·Claudia MarchettiPierluigi Benedetti Panici
Jun 11, 2016·Expert Opinion on Therapeutic Patents·Anita MandhareAsha Gurule
Oct 24, 2017·International Journal of Molecular Sciences·Robert CornelisonCharles N Landen
Apr 25, 2019·Journal of Oncology·Cem SimsekSuayib Yalcin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
T LeM Fung-Kee-Fung
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
J D WrightD G Mutch
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
M A SovakCarol Aghajanian
© 2021 Meta ULC. All rights reserved